ylliX - Online Advertising Network
Company Ticker News

Moderna Is Now More Valued Than Gilead, GlaxoSmithKline: How Long Did COVID-19 Vaccine Maker Take To Hit $100B?

Moderna Is Now More Valued Than Gilead, GlaxoSmithKline: How Long Did COVID-19 Vaccine Maker Take To Hit $100B?

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Moderna Inc (NASDAQ: MRNA) stock is on a roll, with its vaccine-induced momentum spilling over into 2021. The Massachusetts-based company, which had a modest beginning as a tiny biotech startup, has come a long way and is now the 13th most-valued U.S.-listed biopharma.

...read full article on Benzinga

ylliX - Online Advertising Network